Survival

/Survival

Why I Believe Xtandi Is Superior To Zytiga

I believe that Xtandi (enzalutamide) is a superior drug compared to Zytiga (abiraterone). Here's why. The phase III trials for both Xtandi and Zytiga were very similar to each other. In both trials investigators measured the percentage of men who progressed or died against placebo. In this very important measurement Xtandi blew Zytiga out of the [...]

PSA Decline After 4 Weeks of Abiraterone Suggests Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer

Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment response, but it has not been validated as an [...]

What is the Actual Clinical Benefit of Using Low Dose Prednisone Along with Prostate Cancer Chemotherapy with Docetaxel?

Randomized trials have clearly demonstrated that when low dose Prednisone (P) is combined with docetaxel chemotherapy (D) to treat prostate cancer there is a survival benefit. What is the role of the prednisone and does it actually provide any additional benefit to the docetaxel treatment itself? To answer this question a retrospective study was performed [...]

How Quickly You Might Die From Advanced Prostate Cancer Depends On What Organs Are Involved

Researchers at the Duke Cancer Institute along with other cancer centers, in the largest analysis of its kind have found that the organ site where prostate cancer spreads has a direct impact on a man’s survival. They found that men with lymph-only metastasis statistically have the longest overall survival possibility, while those with liver involvement [...]

Side Effects and Toxicity in a Multi-modality Approach Post Radical Prostatectomy with Radiation and ADT

The optimal use and timing of secondary therapy after radical prostatectomy remains controversial despite some new findings supporting the advantages of using aggressive combined secondary therapies was presented at the most recent ASCO GU conference in San Francisco. There are limited data on the patient-reported outcomes following multimodality therapy. Given the move towards increasing combination [...]

The Benefit of Using Local Prostate Cancer Therapy for Men with Lymph Node Positive Disease

In an issue of ONCOLOGY, there was a review of the literature provides us with a comprehensive review of the limited literature on management of men with prostate cancer who have pelvic lymph node involvement but no known distant metastatic disease at diagnosis. Common folklore has been that these men, with limited pelvic lymph node [...]

Combination Chemotherapy And ADT In Hormone Sensitive Prostate Cancer Betters Survival and the Quality Of Life

There is a paradigm shift happening around us in the clinical care of men with metastatic hormone-sensitive prostate cancer. We now know that survival is better when docetaxel chemotherapy is added to androgen-deprivation therapy (ADT), but there have been and still remains concerns about the toxicity of the docetaxel. Recent findings from a new study, [...]

NHS (UK) Fast Tracks Chemotherapy for Men Who Are Still Hormone Sensitive

One of the frustrations faced by men in the UK has been the Guideline that restrictes the use of chemotherapy (docetaxel) to only men who have already failed hormone therapy (ADT). This Guideline directly contradicts the current, cutting edge evidence that, in certain circumstances, earlier chemotherapy increases survival. The good news is that the NHS [...]

REVIEW – Statins Boost Abiraterone (Zytiga) Activity in Prostate Cancer

Another piece of information from the recent ASCO GU conference in San Francisco Researchers have found that adding statin drugs may prolong the sensitivity of abiraterone acetate (Zytiga) in men with castration-resistant prostate cancer (CRPC) To assess the effect of statins on abiraterone therapy, Dr Harshman, of the Lank Center for Genitourinary Oncology at Dana-Farber [...]

German Registry Data Analysis of Degarelix (Firmagon®) for Prostate Cance

The newest gonadotropin-releasing hormone (GnRH) antagonist therapy drug, degarelix (aka Firmagon) has become more commonly used in everyday clinical practice as an alternative hormone therapy treatment drug (ADT). Given that its use has become common it is important to understand both its safety and efficacy as compared to our older standard drugs. The best way [...]